| Autor: |
Tamer Mahmoud El Tantawy, Hanan Abd El-Mawgoud Attia, Heba G Abdel-Aziz, Mayada Mosa Hamed |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Asian Journal of Research in Biochemistry. :43-52 |
| ISSN: |
2582-0516 |
| DOI: |
10.9734/ajrb/2020/v6i430127 |
| Popis: |
Background: Neopterin is a proinflammatorymarker which participates in cell-mediated immunity, and its elevated concentrations declare the presence of interferon-γ in body fluids. In thisstudy, neopterin concentrations were determined in patients with chronic hepatitis C virus (HCV)to assess whether its plasma level can be used to predict the response to antiviral therapy by pegIFNγ combined with ribavirin before starting the treatment. Materials and Mehtods: A total of 54 subjects (all males with an average age of 46.12± 9.89) were included in this study. Neopterin levels were evaluatedby Enzyme-linked immunosorbent assay (ELIZA) in HCV patients treated with peylated interferon combined with ribavirin. Liver function tests (Aspartate aminotransferase, Alanine aminotransferase), albumin and creatinine concentrations were also estimatied. Results: Mean and median pretreatment neopterin levelsshowed no statistically difference between patients with sustained virological response (cured)and non-responders (relapsed) where the concentrations in both groups were≥16 nmol/L.On the other hand, a positive correlation was observed between neopterin level and creatinine at (p ≤ 0.05). Conclusion: Our study suggests that the pretreatment level of neopterin might not be used in routine clinical practice as a marker to predict the response to antiviral therapy in HCVpatients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
